HUM — Humana Inc.

Humana Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Humana reported solid year-to-date performance, tracking to expectations.
• The consolidated operating cost ratio improved by 120 basis points year-over-year, with a full-year reduction expected to be around 150 basis points.
• The company anticipates doubling its individual Medicare Advantage (MA) pretax margin in 2026, excluding Stars-related headwinds.
• Cost trends for 2026 are projected in the high single-digit range (7%-8%), with some favorability noted in inpatient care.

2. Strategic Updates and Business Highlights:

• Humana is focused on achieving a sustainable pretax margin of at least 3% by 2028, with targeted margin expansion expected in 2027.
• The company is prioritizing member retention and improving clinical excellence, which is expected to drive margin improvements.
• Humana has centralized operations to enhance efficiency, including the integration of CarePlus and increased outsourcing in finance and HR functions.
• A recent agreement to divest a minority interest in Gentiva for approximately $900 million will help fund the acquisition of MaxHealth.
• Humana was awarded a statewide Illinois Medicaid managed care contract, set to launch in January 2027.

3. Forward Guidance and Outlook:

• The company remains on track to meet its Investor Day commitments, with a virtual update scheduled for December 10, 2026.
• Humana expects to make significant progress in its 2027 MA bids, with a focus on retaining high-performing plans and exiting lower-performing ones, impacting approximately 600,000 members.
• The company anticipates that the 2027 bids will reflect ongoing clinical excellence and operational efficiency efforts.

4. Bad News, Challenges, or Points of Concern:

• There is uncertainty regarding the impact of the Stars program, with potential litigation outcomes that could affect the competitive landscape.
• The company has acknowledged challenges related to the high cost of drugs, which are expected to increase modestly in 2027.
• Membership losses due to plan exits could impact revenue, although Humana aims to recapture a significant portion of affected members as it did in 2025.
• The company is cautious about the variability in Stars thresholds, which could affect expected outcomes.

5. Notable Q&A Insights:

• Analysts questioned the strategy behind the 2027 bids, particularly regarding margin improvement and the impact of membership size and composition.
• Humana's management emphasized the importance of value-based care in managing costs and improving outcomes, noting that value-based providers are performing better than fee-for-service counterparts.
• The company is focused on simplifying its operations and enhancing service quality through strategic outsourcing and centralization.
• Management reiterated that while they are confident in their operational progress, they cannot guarantee specific Stars outcomes due to inherent uncertainties in the program.

Overall, Humana's Q2 2026 earnings call reflected a company on a positive trajectory, with strategic initiatives aimed at improving margins and member retention, despite facing challenges related to competitive pressures and regulatory uncertainties.